THERAVANCE BIOPHARMA INC (TBPH) Fundamental Analysis & Valuation

NASDAQ:TBPH • KYG8807B1068

Current stock price

16.02 USD
+0.18 (+1.14%)
At close:
16.48 USD
+0.46 (+2.87%)
After Hours:

This TBPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TBPH Profitability Analysis

1.1 Basic Checks

  • In the past year TBPH has reported negative net income.
  • TBPH had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: TBPH reported negative net income in multiple years.
  • In the past 5 years TBPH always reported negative operating cash flow.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

1.2 Ratios

  • TBPH has a better Return On Assets (7.06%) than 88.02% of its industry peers.
  • TBPH's Return On Equity of 12.61% is amongst the best of the industry. TBPH outperforms 87.50% of its industry peers.
Industry RankSector Rank
ROA 7.06%
ROE 12.61%
ROIC N/A
ROA(3y)-2.86%
ROA(5y)16.36%
ROE(3y)-7.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin of TBPH (36.53%) is better than 96.35% of its industry peers.
  • In the last couple of years the Profit Margin of TBPH has declined.
  • The Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 36.53%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-61.3%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TBPH Health Analysis

2.1 Basic Checks

  • TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TBPH has more shares outstanding
  • Compared to 5 years ago, TBPH has less shares outstanding
  • TBPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • TBPH has an Altman-Z score of 0.41. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TBPH (0.41) is comparable to the rest of the industry.
  • TBPH has a debt to FCF ratio of 0.13. This is a very positive value and a sign of high solvency as it would only need 0.13 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.13, TBPH belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
  • TBPH has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.14, TBPH is in line with its industry, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Altman-Z 0.41
ROIC/WACCN/A
WACC9.34%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • TBPH has a Current Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 9.48, TBPH is in the better half of the industry, outperforming 79.69% of the companies in the same industry.
  • A Quick Ratio of 9.48 indicates that TBPH has no problem at all paying its short term obligations.
  • TBPH's Quick ratio of 9.48 is amongst the best of the industry. TBPH outperforms 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 9.48
Quick Ratio 9.48
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TBPH Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.38% over the past year.
  • TBPH shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.21% yearly.
  • The Revenue has grown by 66.92% in the past year. This is a very strong growth!
  • Measured over the past years, TBPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.37% on average per year.
EPS 1Y (TTM)51.38%
EPS 3Y-44.21%
EPS 5YN/A
EPS Q2Q%167.74%
Revenue 1Y (TTM)66.92%
Revenue growth 3Y27.95%
Revenue growth 5Y8.37%
Sales Q2Q%144.7%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.81% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 14.12% on average over the next years. This is quite good.
EPS Next Y281.87%
EPS Next 2Y37.84%
EPS Next 3Y52.59%
EPS Next 5Y26.81%
Revenue Next Year3.59%
Revenue Next 2Y-10.81%
Revenue Next 3Y17.09%
Revenue Next 5Y14.12%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

5

4. TBPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 16.62 indicates a correct valuation of TBPH.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TBPH indicates a rather cheap valuation: TBPH is cheaper than 82.29% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.84. TBPH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 16.62
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, TBPH is valued cheaper than 97.40% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.33
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as TBPH's earnings are expected to grow with 52.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.84%
EPS Next 3Y52.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TBPH Dividend Analysis

5.1 Amount

  • TBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TBPH Fundamentals: All Metrics, Ratios and Statistics

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (4/2/2026, 8:00:01 PM)

After market: 16.48 +0.46 (+2.87%)

16.02

+0.18 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-06
Inst Owners99.38%
Inst Owner Change2.3%
Ins Owners3.96%
Ins Owner Change-6.34%
Market Cap811.73M
Revenue(TTM)107.46M
Net Income(TTM)29.34M
Analysts81.54
Price Target16.49 (2.93%)
Short Float %10.58%
Short Ratio7.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.59%
Min EPS beat(2)-178.66%
Max EPS beat(2)153.48%
EPS beat(4)1
Avg EPS beat(4)-21.5%
Min EPS beat(4)-178.66%
Max EPS beat(4)153.48%
EPS beat(8)2
Avg EPS beat(8)-16.75%
EPS beat(12)4
Avg EPS beat(12)-14.07%
EPS beat(16)4
Avg EPS beat(16)-30.83%
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)-1.36%
Revenue beat(4)1
Avg Revenue beat(4)0.44%
Min Revenue beat(4)-2.67%
Max Revenue beat(4)7.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)4
Avg Revenue beat(12)-3.78%
Revenue beat(16)6
Avg Revenue beat(16)-3.51%
PT rev (1m)-39.48%
PT rev (3m)-39.48%
EPS NQ rev (1m)8.35%
EPS NQ rev (3m)8.53%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)15.03%
Revenue NQ rev (3m)15.18%
Revenue NY rev (1m)14.51%
Revenue NY rev (3m)14.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 16.62
P/S 10.11
P/FCF 3.33
P/OCF 3.33
P/B 3.49
P/tB 3.49
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)0.96
Fwd EY6.02%
FCF(TTM)4.81
FCFY29.99%
OCF(TTM)4.81
OCFY30.02%
SpS1.59
BVpS4.59
TBVpS4.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 7.06%
ROE 12.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 36.53%
GM N/A
FCFM 303.11%
ROA(3y)-2.86%
ROA(5y)16.36%
ROE(3y)-7.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-61.3%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Debt/EBITDA N/A
Cap/Depr -13.08%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 829.74%
Current Ratio 9.48
Quick Ratio 9.48
Altman-Z 0.41
F-Score9
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.38%
EPS 3Y-44.21%
EPS 5YN/A
EPS Q2Q%167.74%
EPS Next Y281.87%
EPS Next 2Y37.84%
EPS Next 3Y52.59%
EPS Next 5Y26.81%
Revenue 1Y (TTM)66.92%
Revenue growth 3Y27.95%
Revenue growth 5Y8.37%
Sales Q2Q%144.7%
Revenue Next Year3.59%
Revenue Next 2Y-10.81%
Revenue Next 3Y17.09%
Revenue Next 5Y14.12%
EBIT growth 1Y16.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2077.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2221%
OCF growth 3YN/A
OCF growth 5YN/A

THERAVANCE BIOPHARMA INC / TBPH Fundamental Analysis FAQ

What is the fundamental rating for TBPH stock?

ChartMill assigns a fundamental rating of 5 / 10 to TBPH.


What is the valuation status for TBPH stock?

ChartMill assigns a valuation rating of 5 / 10 to THERAVANCE BIOPHARMA INC (TBPH). This can be considered as Fairly Valued.


Can you provide the profitability details for THERAVANCE BIOPHARMA INC?

THERAVANCE BIOPHARMA INC (TBPH) has a profitability rating of 3 / 10.


What is the earnings growth outlook for THERAVANCE BIOPHARMA INC?

The Earnings per Share (EPS) of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 281.87% in the next year.